MAIA Biotechnology, Inc. (MAIA)
Oxford Ledge is still expanding full research coverage of MAIA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
MAIA Biotechnology develops ateganosine, a cancer immunotherapy currently in Phase 2 and Phase 3 trials for lung and other cancers.
SEC filings
- 8-K Shareholder vote results 2026-05-22
- 8-K Termination of material agreement 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-11
- 8-K Other material event; Financial statements and exhibits 2026-04-16
- 8-K Other material event; Financial statements and exhibits 2026-04-08
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for MAIA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open MAIA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.